Esta Terapia Está CURANDO Câncer Terminal (Comprovado pela Ciência)

Summary

The video argues that modern healthcare often has economic incentives that favor chronic, ongoing treatments over one-time cures, using investment and pharma logic as examples. It then counters with hopeful evidence suggesting that cures are real and accelerating.

Main claims and reasoning

• Profit models can discourage cures. The creator cites a 2018 Goldman Sachs report stating that therapies that cure patients disrupt companies’ revenue models because cured patients stop buying medicine. The argument is that this “market logic” can steer priorities toward predictable recurring treatment rather than curative breakthroughs.

• Example used: Hepatitis C. A Gilead drug that reportedly “cures” more than 90% of Hepatitis C cases is presented as having sharp revenue decline—from about $12B in 2015 to under $4B by 2018—framed as evidence that cures can reduce long-term commercial demand.

• Not framed as a conspiracy—rather incentives. The video says it’s not a conspiracy, but a system in which investors want predictable cash flow, which can bias what gets funded, developed, and marketed.

Counter-argument: cures are possible and advancing

The video pivots to a “science wins” narrative, using CAR‑T therapy as the centerpiece.

• Dr. Carl H. June and CAR‑T. After the death of his wife to cancer, Dr. Carl H. June is portrayed as dedicating himself to finding a cure. CAR‑T is explained as:

  • extracting a patient’s immune cells,
  • modifying them to recognize cancer,
  • reinfusing them to attack tumors.

• Early funding setbacks. The video attributes some slow progress to a major funding cut after the 2008 financial crisis, claiming NIH support dropped from around ~100 patients to just over 10, making it harder to generate convincing results.

• Landmark remissions as proof-of-concept.

  • Adults with leukemia (e.g., Bill Ludwig) reportedly achieved complete remission after failing conventional treatments.
  • The video highlights Emily Whitehead (age 6): after repeated chemotherapy failures, she receives CAR‑T and is said to become cancer-free. The story includes a severe cytokine-storm complication treated with tocilizumab (IL‑6 blocker), after which she “woke up” and was declared cured.

• Brazil example via SUS (public healthcare).

  • A patient (“Vamberto,” 64) with aggressive lymphoma and widespread disease reportedly received CAR‑T through Hospital das Clínicas (linked to USP), achieved complete remission, and then later died from an unrelated domestic accident shortly afterward. The case is used to argue that curative outcomes are possible even in Brazil.

Why cures aren’t widely used (the “access/price” problem)

• CAR‑T is presented as approved but too costly. The video states CAR‑T is FDA-approved (2017) but emphasizes cost:

  • US cost cited as up to $500,000 per treatment due to personalized, patient-specific manufacturing.
  • Brazil-developed versions are claimed to cost under 500,000 reais, but still remain expensive, delaying broad access.

• System barriers described as practical and daily. The creator argues that doctors and patients can face barriers from insurance/authorization processes and that sometimes important options aren’t offered because of cost (including anecdotal examples involving cholesterol-lowering drugs and insurance delays).

Future outlook: accelerating medicine toward cures

The video claims discovery is speeding up due to:

• AI reducing drug discovery time
• improved manufacturing platforms
• cheaper genomics, citing DNA sequencing cost dropping from ~$30B to around $1,000
• expansion of curative research beyond CAR‑T, including:
  • CAR‑T for solid tumors (pancreatic, lung, breast)
  • vaccines: TB and malaria
  • long-acting antiretroviral injection for HIV prevention
  • CRISPR applications (including cholesterol lowering and broadly “lifetime” intervention concepts)
  • mentions of diabetes “cure” research via engineered pancreatic cells

Final conclusion

The video concludes that even if economic incentives can favor longer treatment, science will not stop, and markets will adapt because cures ultimately create new demand and markets. It ends by contrasting the “don’t cure” premise of the Goldman Sachs report with the claim that the CAR‑T market is now growing rapidly and that tens of thousands of patients have received treatment worldwide, framing the overall message as hopeful: cures can replace hopelessness.

---

Presenters / Contributors

• André Wambier (presenter/creator; cardiologist; stated as “My name is André Wambier, cardiologist, and this is Cardiodf.com.br.”)
• Dr. Carl H. June (immunologist; featured as CAR‑T pioneer)
• Cindy June (named as Carl June’s wife, cancer patient)
• Bill Ludwig (cancer patient mentioned)
• Emily Whitehead (pediatric leukemia patient mentioned)
• Goldman Sachs (cited as the source of a 2018 report)
• Gilead (company cited via the Hepatitis C example)
• NIH (funding source referenced)
• USP (University of São Paulo) (linked to the Brazilian CAR‑T research team referenced)